KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration. (Q51006001)
Jump to navigation
Jump to search
scientific article published on 19 February 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration. |
scientific article published on 19 February 2015 |
Statements
1 reference
KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration. (English)
1 reference
Yusuke Watanabe
1 reference
Takahiko Murata
1 reference
Masahiro Amakawa
1 reference
Yoshihide Miyake
1 reference
Tango Handa
1 reference
Katsuhiko Konishi
1 reference
Yasushi Matsumura
1 reference
Takuji Tanaka
1 reference
Koji Takeuchi
1 reference
19 February 2015
1 reference
754
1 reference
179-189
1 reference
Identifiers
1 reference